01—Abstract
Summary
Summary of the 8-K filed May 2, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders on May 1, 2025.
Of the 123,533,310 shares of common stock outstanding as of the record date, 112,767,003 were represented at the meeting. Stockholders considered three proposals, each described in the company's definitive proxy statement filed with the SEC on March 18, 2025. Stockholders elected two Class III directors, Jeffrey W.
Henderson and Helen I. Torley, to three-year terms expiring at the 2028 Annual Meeting. Henderson received 98,993,463 votes for and 3,298,117 against.
Torley received 101,477,199 votes for and 816,675 against. Each director received affirmative votes from more than a majority of the outstanding shares. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 98,252,464 votes for and 3,966,034 against.
In addition, they ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 112,028,211 votes for and 659,976 against. The filing reports voting results only. It does not describe any new corporate actions, financial results, or changes in governance beyond the matters voted on.
02—Key points
Key Highlights
- Annual Meeting held May 1, 2025, with 112,767,003 of 123,533,310 outstanding common shares represented.
- Jeffrey W. Henderson elected as a Class III director with 98,993,463 votes for and 3,298,117 against; term expires at the 2028 Annual Meeting.
- Helen I. Torley elected as a Class III director with 101,477,199 votes for and 816,675 against; term expires at the 2028 Annual Meeting.
- Advisory vote on named executive officer compensation approved, with 98,252,464 votes for and 3,966,034 against.
- Ernst & Young LLP ratified as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 112,028,211 votes for and 659,976 against.
- Broker non-votes of 10,380,378 were recorded on the director election and say-on-pay proposals.
03—Questions
Frequently Asked Questions
When and where was the 2025 Annual Meeting of Stockholders held?
The filing states that the meeting was held on May 1, 2025. It does not specify a location.
Who was elected to the board at the meeting?
Jeffrey W. Henderson and Helen I. Torley were elected as Class III directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders or until a successor is duly elected and qualified.
Did stockholders approve the executive compensation proposal?
Yes. The advisory vote on the compensation of the named executive officers was approved, with 98,252,464 votes for, 3,966,034 against, and 168,127 abstentions.
Which accounting firm was selected for the fiscal year 2025?
Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 112,028,211 votes for, 659,976 against, and 78,816 abstentions.
Where can investors find more detail on the proposals?
The filing states that each proposal is described in more detail in the company's definitive proxy statement filed with the SEC on March 18, 2025.
04—Continue